Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network.
18 affiliations
- 1Children's Mercy Kansas City and University of Missouri-Kansas City, Kansas City, Missouri, USA.
- 2Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta, Canada.
- 3St. Louis Children's Hospital, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
- 4University of Florida College of Pharmacy and Nemours Children's Health, Jacksonville, Florida, USA.
- 5Children's Minnesota, Minneapolis/St. Paul, Minnesota, USA.
- 6Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- 7Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- 8School of Pharmacy, University of Jordan, Amman, Jordan.
- 9School of Pharmacy, University of the Western Cape, Cape Town, South Africa.
- 10Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
- 11Personalized Medication Management Unit, Department of Pharmaceutical Services and Sciences, Children's Cancer Hospital Egypt 57357, Cairo, Egypt.
- 12Children's Hospital Los Angeles, Los Angeles, California, USA.
- 13Sanford Imagenetics, Sanford Health, Sioux Falls, South Dakota, USA.
- 14Department of Internal Medicine, University of South Dakota School of Medicine, Vermillion, South Dakota, USA.
- 15MedStar Health, Columbia, Maryland, USA.
- 16Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
- 17Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
- 18Arkansas Children's Hospital, Little Rock, Arkansas, USA.
Abstract
Descriptions of how pediatric-focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult-focused institutions. We aimed to provide a detailed description of how pediatric-focused institutions across the world implemented pharmacogenomic testing in clinical practice. A survey was distributed to members of the Pharmacogenomics Global Research Network to assess program infrastructure, implementation efforts, genes tested, method of testing, and clinical decision support. The survey was completed by 43 institutions that have implemented pharmacogenomics: 12 pediatric-focused, 10 adult-focused, and 21 institutions serving all ages. All pediatric-focused institutions provide testing for CYP2C19, CYP2C9, CYP2D6, CYP3A5, NUDT15, and TPMT. Psychiatry and hematology/oncology were the specialties most commonly reported as implementing pharmacogenomics at pediatric-focused institutions. Most institutions have clinical decision support incorporated into their electronic health record and a similar number of compensated employees contributing to the program, regardless of age group focus. All pediatric-focused institutions were non-profit and often received programmatic funding from internal sources. A higher proportion of pediatric-focused sites provided patient education (92%) compared to adult-focused (60%) and those caring for all ages (76%). Pediatric-focused institutions interested in implementing or expanding their pharmacogenomic services will encounter many of the same opportunities and considerations as adult institutions. The results of this survey highlight additional unique considerations for pediatric-focused pharmacogenomic implementation and may serve as a roadmap for pediatric institutions interested in implementing or expanding pharmacogenomic services.
Related
- Knowledge and experience of caring for cancer survivors by physicians and advanced practice providers: an implementation-focused mixed-methods research
- Metabolic abnormalities in pediatric pulmonary arterial hypertension: a narrative review of direct evidence, mechanistic boundaries, and a validation-focused research agenda.
- Defining Core Functions and Forms for the Implementation of Pharmacogenomics Testing in Primary Care
- The pharmacokinetics and pharmacogenomics of voriconazole in pediatric Saudi patients: advancing toward precision medicine.
- School-based high-intensity interval training for children: a focused systematic review of implementation and school-relevant outcomes
BibTeX
@article{ramsey2026implementation,
title = {{Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network.}},
author = {Laura B Ramsey and Chad Bousman and Rebecca Brand and Kelsey Cook and David B Gregornik and Cyrine E Haidar and Nancy Hakooz and Nicole Keuler and Nathan Lamb and Mohamed Nagy and Jenny Q Nguyen and Courtney Paetznick and April Schultz and D Max Smith and Evangelia Eirini Tsermpini and Amanda L Elchynski},
journal = {Clinical pharmacology and therapeutics},
year = {2026},
month = nov,
doi = {10.1002/cpt.70553},
url = {https://europepmc.org/article/MED/42998038},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Implementation of Pharmacogenomics in Pediatric-Focused Institutions Within the Pharmacogenomics Global Research Network.
AU - Laura B Ramsey
AU - Chad Bousman
AU - Rebecca Brand
AU - Kelsey Cook
AU - David B Gregornik
AU - Cyrine E Haidar
AU - Nancy Hakooz
AU - Nicole Keuler
AU - Nathan Lamb
AU - Mohamed Nagy
AU - Jenny Q Nguyen
AU - Courtney Paetznick
AU - April Schultz
AU - D Max Smith
AU - Evangelia Eirini Tsermpini
AU - Amanda L Elchynski
PY - 2026
DA - 2026/11/07
JO - Clinical pharmacology and therapeutics
DO - 10.1002/cpt.70553
UR - https://europepmc.org/article/MED/42998038
AB - Descriptions of how pediatric-focused institutions implement pharmacogenomic testing are scarce, and often not differentiated from adult-focused institutions. We aimed to provide a detailed description of how pediatric-focused institutions across the world implemented pharmacogenomic testing in clinical practice. A survey was distributed to members of the Pharmacogenomics Global Research Network to assess program infrastructure, implementation efforts, genes tested, method of testing, and clinical decision support. The survey was completed by 43 institutions that have implemented pharmacogenomics: 12 pediatric-focused, 10 adult-focused, and 21 institutions serving all ages. All pediatric-focused institutions provide testing for CYP2C19, CYP2C9, CYP2D6, CYP3A5, NUDT15, and TPMT. Psychiatry and hematology/oncology were the specialties most commonly reported as implementing pharmacogenomics at pediatric-focused institutions. Most institutions have clinical decision support incorporated into their electronic health record and a similar number of compensated employees contributing to the program, regardless of age group focus. All pediatric-focused institutions were non-profit and often received programmatic funding from internal sources. A higher proportion of pediatric-focused sites provided patient education (92%) compared to adult-focused (60%) and those caring for all ages (76%). Pediatric-focused institutions interested in implementing or expanding their pharmacogenomic services will encounter many of the same opportunities and considerations as adult institutions. The results of this survey highlight additional unique considerations for pediatric-focused pharmacogenomic implementation and may serve as a roadmap for pediatric institutions interested in implementing or expanding pharmacogenomic services.
SN - 0009-9236
SN - 1532-6535
ER -